

TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION

5

The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R]-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide, to its anhydrous form, to its
10 crystallisation in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.

BACKGROUND TO THE INVENTION

15

A number of dihydropteridione derivatives are already known in the prior art. Thus, for example, International Patent Applications WO 03/020722 and WO 2004/076454 disclose dihydropteridione derivatives, a process for their manufacture and their use in a pharmaceutical composition to treat diseases connected with the activity of specific
20 cell cycle kinases and characterised by excessive or abnormal cell proliferation.

The compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R]-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide and a process for its manufacturing are specifically disclosed in
25 WO 2004/076454.

However, the above-mentioned patent applications do not disclose any specific salt form or crystal form of any of the compounds exemplified therein.

30 Although the pharmacologically valuable properties of the dihydropteridinone derivatives disclosed in the art and mentioned above constitute the basic prerequisite for effective use of the compounds as pharmaceutical compositions, an active substance must in any case satisfy additional requirements in order to be accepted for use as a drug. These parameters are largely connected with the physicochemical
35 nature of the active substance. Hence, there continues to be a need for novel salt and crystalline forms of active substances, which can be conveniently formulated for

administration to patients and which are pure and highly crystalline in order to fulfil exacting pharmaceutical requirements and specifications.

Preferably, such compounds will be readily formed and have favourable bulk characteristics. Examples of favourable bulk characteristics are drying times, filterability, solubility, intrinsic dissolution rate, stability in general and especially thermal stability, and hygroscopicity.

An absence of breakdown products in the pharmaceutical composition being used is also favourable, since if breakdown products are present in the pharmaceutical composition the content of active substance present in the pharmaceutical formulation might be lower than specified.

Another critical parameter to be controlled is the hygroscopicity, since the absorption of moisture reduces the content of pharmaceutically active substance as a result of the increased weight caused by the uptake of water. Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g. by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture. In addition, the uptake of moisture may reduce the content of pharmaceutically active substance during manufacture if the pharmaceutical substance is exposed to the environment without being protected from moisture in any way. Preferably, therefore, the hygroscopicity of a pharmaceutically active substance should be well characterised, and possibly also stabilized.

As the crystal modification of an active substance is important to the reproducible active substance content of a preparation, there is a need to clarify as far as possible any existing polymorphism of an active substance present in crystalline form. If there are different polymorphic modifications of an active substance care must be taken to ensure that the crystalline modification of the substance does not change in the pharmaceutical preparation later produced from it. Otherwise, this could have a harmful effect on the reproducible potency of the drug. Against this background, active substances characterised by only slight polymorphism are preferred.

Decreased levels of organic solvents in the crystal lattice are also favourable, due in part to potential solvent toxicity to the recipient as a function of the

solvent.

Another criterion which may be of exceptional importance under certain circumstances depending on the choice of formulation or the choice of manufacturing process is the solubility of the active substance. If for example pharmaceutical solutions are prepared (e.g. for infusions) it is essential that the active substance should be sufficiently soluble in physiologically acceptable solvents. For drugs which are to be taken orally, it is in general very important that the active substance should be sufficiently soluble and bioavailable.

10

Furthermore, the process for preparing such a compound also needs to be conveniently carried out on commercial scale.

Hence, without being restrictive, examples of the parameters which needs to be controlled are the stability of the starting substance under various environmental conditions, the stability during production of the pharmaceutical formulation and the stability in the final compositions of the drug.


The pharmaceutically active substance used to prepare the pharmaceutical compositions should therefore have great stability which is ensured even under all kinds of environmental conditions.

The problem of the present invention is thus to provide a pharmaceutically active substance which is not only characterised by high pharmacological potency but also satisfies the above-mentioned physicochemical requirements as far as possible.

SUMMARY OF THE INVENTION

Surprisingly, it has been found that the problem outlined above is solved by the trihydrochloride salt and by the crystalline trihydrochloride hydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxybenzamide, the structure of which is depicted below in the form of the free base as formula (I).

35



(II)

The trihydrochloride salt and the crystalline trihydrochloride hydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxybenzamide offer numerous advantages over the free base and the anhydrous form of this compound. Hence, over the anhydrous form, the crystalline trihydrochloride hydrate form presents for example an advantage of stability under ambient conditions.

Furthermore, when compared to the base salt, the trihydrochloride salt presents an advantage of solubility in water, where the trihydrochloride is much more soluble than the free base.

Lastly, when compared to other common salt form builders, the trihydrochloride salt form presents also advantages as far as the yield, purity and reproducibility of the synthesis of the salt form are concerned.

Thus, a first object of the present invention is the trihydrochloride salt form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxybenzamide.

A further object of the present invention is the trihydrochloride anhydrous form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxybenzamide.

A further object of the present invention are the crystalline trihydrochloride hydrate forms of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide.

5

A further object of the present invention is the crystalline trihydrochloride trihydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide.

10

A further object of the present invention is an improved process for the manufacturing of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide.

15

A further object of the present invention is a process for the manufacturing of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide.

20

A further object of the present invention is a pharmaceutical composition comprising the trihydrochloride salt, a crystalline trihydrochloride hydrate form or the crystalline trihydrochloride trihydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide, together with one or more pharmaceutically acceptable carriers, diluents or excipients.

25

A further object of the present invention is the use of the trihydrochloride salt, a crystalline trihydrochloride hydrate form or the crystalline trihydrochloride trihydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide, in a method for treating diseases characterised by excessive or abnormal cell proliferation, or for preparing a pharmaceutical composition which is suitable for treating diseases characterised by excessive or abnormal cell proliferation.

35

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the X-ray powder diffractogram of the crystalline trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, recorded using a Bruker D8 Advanced-diffractometer fitted with a location-sensitive detector (OED) and a Cu anode as the x-ray source (CuK α radiation, λ = 1.54056 Å, 40 kV, 40 mA).

Figure 2 shows a light microscopy photograph of crystals of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide.

Figure 3 shows the thermoanalysis and determination of the melting point (DSC/TG) of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, recorded using a DSC and evaluated by the peak onset (heating rate: 10°C/min). The value given is determined using a DSC 821e made by Mettler Toledo.

DETAILED DESCRIPTION OF THE INVENTION

As already mentioned hereinbefore, the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide is specifically disclosed in WO 2004/076454, as well as a process for its preparation. For details on a process to manufacture this compound, reference is thus made to this patent application.

For an alternative process to manufacture this compound, reference is made to the following process.

Abbreviations used.


TLC Thin-Layer Chromatography
DSC Differential Scanning Calorimeter
TG ThermoGravimetry

- 5 The starting materials trans-4-aminocyclohexanol **10**, 3-methoxy-4-nitrobenzoic acid **2**, N-(cyclopropylmethyl)piperazine **12c**, and 4-acetamido-cyclohexanone **18** are known compounds which are commercially available.


This process is a convergent process, which includes the steps of:

10

- (i) synthesis of a compound of formula **15c**




- 15 (ii) synthesis of a compound of formula **16**




and (iii) reacting the compound of formula **15c** with the compound of formula **16**.

- 20 In the foregoing, the synthesis of a compound of formula **15c** and the synthesis of a compound of formula **16** are described.


- (i) Synthesis of a compound of formula **15c**



- 260g (1.32 mol) 3-methoxy-4-nitrobenzoic acid **2** are placed in 1.5 L toluene. 300 mL
 5 toluene are distilled off. 5 mL dimethylformamide are added to the residue and 123 mL
 (1.7 mol) thionyl chloride are added dropwise thereto. The reaction solution is refluxed
 for 2 hours. The solvent is concentrated by evaporation using the rotary evaporator
 under reduced pressure. The residue is dissolved in 500 mL tetrahydrofuran and added
 dropwise to a suspension of 202g (1.33 mol) trans-4-aminocyclohexanol **10** in 1.5 L
 10 tetrahydrofuran and 1.38 L of a 30% potassium carbonate solution, so that the
 temperature is maintained between 5° and 13°C. The mixture is stirred for 1 hour at
 20°C and 5 L demineralised water are added. The precipitate is suction filtered and
 washed with demineralised water. The solid is dried at 70°C in the circulating air dryer.
 380g (98% of theory) product **11** are obtained.
 15 TLC (methylene chloride/ethanol = 9:1) $R_f = 0.47$




- 1 g of finely powdered ruthenium(III)-chloride hydrate are added to 185g (0.63 mol) **11**
 20 and 234g N-methylmorpholine-N-oxide in 1.8 L acetonitrile and the mixture is refluxed
 for 1 hour. Under reduced pressure 1.6 L acetonitrile are evaporated off. 1.5 L
 demineralised water are added to the residue and the suspension is cooled to 5°C. The
 precipitate is suction filtered and washed with plenty of demineralised water. The solid
 is dried at 70°C in the circulating air dryer. 168g (91% of theory) product **13** are
 25 obtained.
 TLC (methylene chloride/ethanol = 9:1) $R_f = 0.64$



112g (383 mmol) of product **13**, 108g (770 mmol) N-(cyclopropylmethyl)piperazine **12c** and 4.5 mL methanesulphonic acid in toluene are refluxed for 3 hours using the water separator (approx. 76 mL water are separated off). Under reduced pressure 900 mL toluene are evaporated off and the residue is suspended in 1.2 L ethanol. 15g sodium borohydride are added batchwise to this suspension at a temperature of 15° to 25°C within one hour. The mixture is stirred for 3 hours at 20°C and another 4g sodium borohydride are added. The mixture is stirred for 16 hours at 20°C. Under reduced pressure 650 mL ethanol are evaporated off. 2 L demineralised water and 300 mL cyclohexane are added. The mixture is cooled to 5°C and the suspension is suction filtered. The residue is dissolved in 1 normal hydrochloric acid. 5g activated charcoal are added and the mixture is suction filtered. 400 mL tert.-butylmethylether are added to the filtrate and it is made alkaline with ammonia solution. It is cooled to 4°C, the precipitate is suction filtered and washed with demineralised water. The residue is refluxed in 400 mL tert.-butylmethylether. It is cooled, the solid is suction filtered and washed with tert.-butylmethylether. After drying in the circulating air dryer at 60°C 73g (46% of theory) product **14c** is obtained.

TLC (methylene chloride/ethanol = 9:1) $R_f = 0.2$


The compound **14c** may alternatively also be prepared by the following method.




22g (142 mmol) 4-acetamido-cyclohexanone **18**, 39.7g (283 mmol) N-cyclopropylmethylpiperazine **12c** and 0.71 mL methanesulphonic acid in 175 mL toluene are refluxed using the water separator until no more water is precipitated. The mixture is left to cool and at 50°C 175 mL ethanol are added and the resulting mixture

is cooled to 20°C. 5.37g (142 mmol) sodium borohydride are added batchwise with thorough stirring and the mixture is stirred for 16 hours at 20°C. 200 mL of 4 normal hydrochloric acid are added dropwise to the reaction mixture. Under reduced pressure 200 mL solvent are evaporated off. 100 mL saturated potassium carbonate solution and 200 mL methylisobutylketone are added to the residue. The two-phase mixture is cooled to 5°C with thorough stirring. The product is suction filtered and dissolved at reflux temperature in 90 mL methylisobutylketone. After the addition of activated charcoal it is filtered hot. The mixture is left to cool and the precipitate is removed by suction filtration. After drying, 16.2g (41% of theory) of *trans* compound **19** are obtained.

TLC (methylene chloride/ethanol/ammonia = 9:1:0.1) $R_f = 0.39$




A solution of 44g (157 mmol) of product **19** in 500 mL 24% hydrochloric acid is refluxed for 6 hours. The solvent is concentrated by evaporation under reduced pressure and the residue is crystallised from 700 mL isopropanol. The precipitate is suction filtered, washed with tert.-butylmethylether and dried at 60°C in the vacuum drying cupboard. 54.7g product **20** are obtained as the trihydrochloride (contains 5% water).



33g (90.4 mmol) 3-methoxy-4-nitrobenzoic acid **2** are suspended in 80 mL toluene. 0.5 mL dimethylformamide and 16g (134 mmol) thionyl chloride are added. The mixture is refluxed for 1 hour. The solution is concentrated by evaporation under reduced pressure and the crude acid chloride is dissolved in 50 mL tetrahydrofurane. The solution is added dropwise to a suspension of 18.7g (94.9 mmol, 95%) of **20**

trihydrochloride and 49g (397 mmol) of diisopropylethylamine in 150 mL tetrahydrofuran while being cooled in the ice bath. TLC is used to check that the reaction is complete. After the reaction has ended water is added to the suspension and the pH is adjusted to 10 by the addition of sodium hydroxide solution. The organic phase is separated off and washed with saturated saline solution. The combined aqueous phases are extracted once with tetrahydrofuran. The combined organic phases are concentrated by evaporation under reduced pressure. The residue is refluxed in 300 mL tert.-butylmethylether. The mixture is left to cool to 20°C and the precipitate is suction filtered. After drying in the vacuum drying cupboard at 45°C, 31.3g (83% of theory) of product **14c** is obtained.



A solution of 72.5g (174 mmol) of product **14c** in 700 mL methanol and 145 mL dimethylformamide is hydrogenated in the presence of 10g Raney nickel at a temperature of 20°C and a hydrogen pressure of 50psi. The catalyst is filtered off and the methanol is evaporated under reduced pressure. 500 mL demineralised water are added to the residue and the suspension is cooled to 5°C. The precipitate is suction filtered and washed with demineralised water. After drying in the circulating air dryer at 60°C, 60.5g (90% of theory) of product **15c** is obtained.

TLC (methylene chloride/ethanol/ammonia = 9:1:0.1) R_f = 0.58


(ii) Synthesis of a compound of formula **16**

25

The synthesis of the 2-chloro-7-ethyl-7,8-dihydro-5-methyl-8-(1-methylethyl)-(7*R*)-6(5*H*)-pteridinone **16** is described in general in WO 2004/076454, to which reference is made.


The present invention provides an alternative route of synthesis of the 2-chloro-7-ethyl-7,8-dihydro-5-methyl-8-(1-methylethyl)-(7*R*)-6(5*H*)-pteridinone **16**, which is described in the following.

- 5 The following starting materials are known and commercially available: (R)-2-amino-butyric acid **21** and 2,4-dichloro-5-nitropyrimidine **5**.




- 10 A suspension of 25 g (242 mmol) (R)-2-amino-butyric acid **21** and 32 mL (290 mmol) trimethylorthoformate in 150 mL methanol is heated to 50 °C. At this temperature 26.5 mL (364 mmol) of thionylchloride are added in 30 minutes. Under evolution of gas the temperature increases to 60 °C. The reaction mixture is refluxed for 3 hours. 125 mL methanol are distilled off and 100 mL toluene are added. 75 mL of solvent are
- 15 removed by distillation. A suspension of 77 g (364 mmol) sodium triacetoxymorohydride in 175 mL toluene is added to the reaction mixture at 60 °C. 22 mL acetone are added at 40 °C. The reaction mixture is stirred for 16 hours at room temperature. Under cooling 73 mL ammonia (25%) is added. After addition of 50 mL of demineralised water the mixture is heated to 50°C. The organic phase is separated and washed with
- 20 demineralised water. 24 mL of a 10 molar solution of hydrogenchloride in ethanol is added. 125 mL of solvent are removed by distillation. 175 mL tetrahydrofurane is added and the suspension is cooled to 2 °C. The suspension is suction filtered and washed with cold tetrahydrofurane. After drying in a vacuum drying oven at 50°C, 42.9 g (90% of theory) of product **22** as hydrochloride is obtained.

25




9.3 mL of a 50% aqueous sodium hydroxide solution is added to a stirred mixture of 33.3 g (170 mmol) **22** hydrochloride in 60 mL cyclohexane and 60 mL demineralised water. The aqueous phase is separated and the organic phase is added dropwise to a refluxed suspension of 30 g (155 mmol) **5** and 52 g (619 mmol) sodium hydrogencarbonate in 230 mL cyclohexane. The suspension is refluxed for 5 hours using a water separator to remove the formed water. 75 mL of solvent is distilled off. At 75 °C the suspension is suction filtered to remove the salts. The solvent is distilled off. The residue is dissolved in 240 mL 2-propanol and 90 mL of solvent is distilled off again. The solution is cooled slowly to 2 °C. The suspension is suction filtered and washed with cold 2-propanol. After drying in a vacuum drying oven at 50°C, 38.9 g (79% of theory) of product **23** is obtained

Lipophilic solvents such as e.g. cyclohexane, methylcyclohexane, toluene and the mixtures thereof are particularly suitable for achieving high regioselectivity in the nucleophilic substitution reaction with compound **5**.




50 g **23** in 375 mL of tetrahydrofuran is hydrogenated in the presence of 5 g Platinum on Carbon (5%) at a hydrogen pressure of 3 bar and at 35 °C until no further hydrogen is consumed. 2.5 g vanadyl acetylacetonate are added and the hydrogenation is continued. The suspension is filtered to remove the catalysts. The solvent is removed under reduced pressure. 150 mL 2-propanol are added to the residue and heated to reflux. 300 mL of demineralised water are added. The suspension is cooled slowly to 2 °C. The suspension is suction filtered and washed with a cold mixture of 2-propanol and demineralised water. After drying in a vacuum drying oven at 50°C, 36 g (90% of theory) of product **24** is obtained



A suspension of 7 g (27.5 mmol) of product **25** and 5.7 g (41 mmol) potassium carbonate in 30 mL dimethylcarbonate is heated to 130°C in an autoclave for 5 hours.

- 5 The mixture is left to cool and 25 mL demineralised water and 15 mL ethyl acetate are added with stirring. The organic phase is distilled off under reduced pressure. A mixture of 25 mL ethanol and 45 mL demineralised water is added to the residue and heated to 60°C. The solution is left to cool to room temperature. The precipitate is suction filtered and washed with a mixture of demineralised water and ethanol (2:1). The product is
- 10 dried at 50°C in the vacuum drying cupboard. 6 g (82% of theory) of product **16** are obtained.

(iii) Reaction of a compound of formula **15c** with a compound of formula **16**




15


- A solution of 23g (59.5 mmol) of compound **15c**, 16.8g (62.5 mmol) 2-chloro-7-ethyl-7,8-dihydro-5-methyl-8-(1-methylethyl)-(7R)-6(5H)-pteridinone **16** and 28.3g (149 mmol) para-toluenesulphonic acid hydrate in 350 mL 2-methyl-4-pentanol is refluxed
- 20 for 22 hours using the water separator. After the addition of 1g of compound **16** the mixture is refluxed for a further 2 hours. 300 mL solvent are distilled off and the viscous oil is allowed to cool to 60°C. 300 mL methylene chloride and 300 mL demineralised water are added and the pH is raised by adding approx. 20 mL of 10 normal sodium hydroxide solution to pH = 9. The organic phase is washed twice with demineralised
- 25 water and dried over sodium sulphate. The solvent is evaporated off under reduced pressure and the residue is dissolved at 65°C in 200 mL ethyl acetate. The mixture is left to cool slowly to 20°C, the precipitate is suction filtered and washed with cold ethyl

acetate. After drying at 60°C in the vacuum drying cupboard 24.4g (66% of theory) of product **(I)** is obtained (m.p. = 182°C, DSC: 10 K/min, additional endothermic effects in the DSC diagram before melting).


- 5 Thus, it is an object of the present invention to provide a process for the manufacture of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula **(I)**

**(I)**


characterised in that a compound of formula **15c**

**15c**

is reacted with a compound of formula **16**,

**16**

wherein the compound of formula **16** is prepared by methylation of a compound of formula **8**

**8**

5

in the presence of dimethylcarbonate.

The present invention further provides a process for the manufacture of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[**(7R)**-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I), said process comprising the steps of contacting, under elevated temperature or at room temperature, N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[**(7R)**-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide dissolved in a suitable solvent or in a mixture of solvents, with hydrochloric acid or hydrogen chloride gas dissolved in an organic solvent, optionally in the presence of para-toluenesulfonic acid, and collecting the precipitate formed. Suitable solvents to dissolve N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[**(7R)**-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide for performing the salt formation are alcohols like methanol, ethanol, 1- or 2-propanol, isomeric alcohols of butanol, isomeric alcohols of pentanol, isomeric alcohols of hexanol, like 2-methyl-4-pentanol, ketones like acetone, dialkylethers like tetrahydrofuran, acetic acid esters like ethyl acetate, organic acids like acetic acid, amides like N-methylpyrrolidinone and nitriles like acetonitrile.

25

An alternative manufacturing process is illustrated by the following experiment, in which the trihydrochloride salt is obtained by addition of concentrated hydrochloric acid to the reaction medium after completion of the acid mediated nucleophilic aromatic substitution reaction of the compound **15c** with the compound **16**. The following

example is illustrative of the present invention and therefore is not to be regarded as a limitation to its scope.

5 A suspension of 143 g (0.37 mol) **15c** and 110 g (0.41 mol) **16** in 2 L 2-methyl-4-pentanol is heated up to 60 °C. 176 g (0.93 mol) para-toluenesulfonic acid monohydrate are added and the mixture is heated to reflux for 24 hours using a water separator. The solution is cooled to 100 °C. 183 g concentrated hydrochloric acid are added. At 60 °C 1.5 L acetone are added. The suspension is stirred for 16 hours at room temperature. The precipitate is suction filtered
10 and washed with acetone. The product is dried at 60°C in the vacuum drying cupboard. 267 g (92% of theory) of compound (I) as trihydrochloride are obtained.

A further object of the present invention is the following step of purification of the
15 trihydrochloride salt via crystallization, wherein:

the compound (I) as trihydrochloride is suspended in a suitable organic solvent, such as ethanol;

20 the reaction medium is heated to reflux;

water is added;

after cooling the precipitate is collected, washed with a suitable solvent, such as
25 ethanol, and dried.

The following example of purification via crystallization is illustrative of the present invention and therefore is not to be regarded as a limitation to its scope.

30 Example of purification of the trihydrochloride salt of the compound of formula (I) via crystallization.

A suspension of 15.5 g of compound (I) as trihydrochloride in 160 mL dry ethanol is heated to reflux. 5.5 mL of demineralised water are added. The
35 solution is left to cool slowly to 20°C and stirred 16 hours at 20 °C. The

precipitate is suction filtered and washed with ethanol. After drying at 50°C in the vacuum drying cupboard 13.3 g (86% of theory) of compound (I) as trihydrochloride is obtained.

- 5 A further object of the present invention is a process for the manufacture of an hydrated crystal form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I), said process comprising the steps of:

10

dissolving the compound (I) as base in a suitable organic solvent, such as ethanol, at room temperature or elevated temperature;

adding hydrochloric acid to the reaction medium;

15

cooling the reaction medium;

collecting the precipitate, washing the precipitate with e.g. ethanol, and drying.

- 20 The following example of manufacture of an hydrated crystal form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I) is illustrative of the present invention and therefore is not to be regarded as a limitation to its scope.


25

Example of manufacture of an hydrated crystal form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I).

30

1.1 g of concentrated hydrochloric acid are added to a solution of 2 g of the free base of (I) in 30 mL ethanol. After stirring for 2 hours at 20 °C the suspension is cooled to 2 °C. The precipitate is suction filtered and washed with ethanol. After drying in the vacuum drying cupboard 2.15 g (91% of theory) of product (I) as trihydrochloride are
35 obtained.

The trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I), is represented by the following Formula.



10

$$\text{C}_{34}\text{H}_{50}\text{N}_8\text{O}_3 \times 3 \text{ HCl}$$

MW = 728.21

The present invention also provides a process for the manufacture of an anhydrous form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I), wherein a preparation of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) is dried at a temperature above 130°C and maintained under dry atmosphere.

The following solubility and solid state characteristics of an hydrated form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I), are relevant to the present invention.

Solubility properties of an hydrated form of the trihydrochloride salt of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide.

5

Solubility in aqueous media

Table I shows the values of solubility of an hydrated form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I) in different aqueous media.

10

Table I

15

Medium	Solubility [mg/ml]	pH of the saturated solution
water	> 10	3.7
0.1 N HCl	> 10	1.3
0.01 N HCl	> 10	n.d.
0.1 mol/l citric acid	> 10	n.d.
0.1 mol/l tartaric acid	> 10	n.d.
0.01 mol/l methanesulfonic acid	> 10	n.d.
Mcllvaine buffer pH 2.2	>10	2.3
Mcllvaine buffer pH 3.0	6.2	3,0
Mcllvaine buffer pH 4.0	7.2	3.9
Mcllvaine buffer pH 5.0	7.2	4.7
Mcllvaine buffer pH 6.0	7.1	5.7
Mcllvaine buffer pH 7.4	7.8	7.1
0.1 mol/l meglumine	0.017	pH 8.9
0.01 N NaOH	> 10	pH 7.4

n.d. = not determined

From the above results, it can be concluded that this hydrated form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) has a pH dependent solubility profile in aqueous media with high solubility in acidic and neutral media and strongly reduced solubility in basic media due to the lower solubility of the free base.

Solubility in organic media

10

This hydrated form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) is highly soluble (> 10 mg/ml) in propylenglycol, glycofurol, Cremophor RH40 (30 % aqueous solution), Poloxamer 188 (20 % aqueous solution), Solutol HS 15 (20 % aqueous solution) as well as HP- β -cyclodextrin (20 % -, 10 % -, 5 % - aqueous solutions).

20

Solid state properties of an hydrated form of the trihydrochloride salt of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide.

Appearance

25

In the solid state, this hydrated form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) appears as a white to off-white microcrystalline powder.

30

Crystallinity and polymorphism

This hydrated form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-

methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) is highly crystalline. The X-ray powder diffraction diagram is shown in Figure 1.

The X-ray powder reflection and intensities (standardised) are shown in the following Table II.

Table II

2 Θ [°]	d_{hkl} [Å]	Intensity I/I_o [%]
4.13	21.38	24
7.88	11.21	89
8.25	10.71	34
8.66	10.21	28
9.81	9.01	100
11.45	7.73	54
12.38	7.14	59
13.12	6.74	37
13.50	6.55	52
14.53	6.09	39
15.26	5.80	32
15.40	5.75	32
15.51	5.71	37
16.52	5.36	43
16.71	5.30	28
17.35	5.11	10
18.04	4.91	43
18.19	4.87	42
18.65	4.75	32

19.10	4.64	19
19.56	4.53	79
19.64	4.52	82
20.40	4.35	24
20.69	4.29	14
21.15	4.20	28
21.49	4.13	52
22.07	4.02	7
22.42	3.96	16
22.86	3.89	40
23.33	3.81	16
23.81	3.73	51
24.08	3.69	16
24.25	3.67	22
24.57	3.62	38
25.24	3.53	22
25.40	3.50	24
25.78	3.45	13
26.08	3.41	48
26.45	3.37	32
26.70	3.34	22
27.12	3.29	31
27.45	3.25	28
27.68	3.22	13
28.13	3.17	6
29.24	3.05	28
29.56	3.02	22
29.94	2.98	14

30.12	2.96	22
30.39	2.94	9
31.04	2.88	32
31.29	2.86	15
31.64	2.83	6
32.16	2.78	8
32.69	2.74	8
32.92	2.72	21

In Table II above the value " $2\Theta [^\circ]$ " denotes the angle of diffraction in degrees and the value " $d_{hkl} [\text{\AA}]$ " denotes the specified distances in $\text{\AA}$ between the lattice planes.

5

According to the findings shown in Table II the present invention further relates to the crystalline trihydrochloride trihydrate salt form of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, characterised in that in the x-ray powder diagram it has, inter alia, the characteristic values $d = 3.73 \text{ \AA}$, $4.13 \text{ \AA}$, $4.52 \text{ \AA}$, $4.53 \text{ \AA}$, $6.55 \text{ \AA}$, $7.14 \text{ \AA}$, $7.73 \text{ \AA}$, $9.01 \text{ \AA}$ and $11.21 \text{ \AA}$ (most prominent peaks in the diagram).

10

The material crystallizes in rod like crystals, as shown in enclosed Figure 2.

15

Under standard conditions the crystalline trihydrochloride salt form of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide according to the invention is present in the form of an hydrate and is obtainable after drying with a changing stoichiometry (1-3 water equivalents). The hydrate with a stoichiometry close to a trihydrate seems to be the stable hydrated form under ambient conditions and can be obtained after conditioning of the dried material. The crystal water is tightly bound. Lowering the humidity down to 10 % r.h. does not result in a significant weight loss.

20


Thus, the present invention further relates to the crystalline trihydrochloride salt of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide, characterised in that it is in a trihydrate form.

5

The thermoanalysis of the crystalline form of the crystalline trihydrochloride salt of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide according to the invention shows a $T_{fus} = 245 \pm 5 \text{ }^{\circ}\text{C}$ (DSC: $10 \text{ K}\cdot\text{min}^{-1}$ heating rate), under decomposition, and a broad endothermic effect between $60 - 140 \text{ }^{\circ}\text{C}$, corresponding with the release of water. The DSC/TG diagram is shown in Figure 3. A closer look to the TG-trace shows a weight loss of approx. $7.5 \pm 0.5 \text{ wt. } - \%$ between 60 and 140°C . This weight loss can be attributed to the release of occluded crystal water.

Correlating the observed weight loss with the molecular weight of the trihydrochloride salt of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide reveals a stoichiometry of the respective hydrated form close to a trihydrate.

20



At about $260 \text{ }^{\circ}\text{C}$ another strong endothermic peak can be observed in the DSC-diagram, indicating melting of the dehydrated form. The onset of this melting event is at about $245 \text{ }^{\circ}\text{C}$. Melting occurs, however, under decomposition, indicated by the accompanied weight loss upon melting. When performing a TG-IR coupling experiment, it can be shown that hydrochloric acid is released upon decomposition.

The respective anhydrous form, obtained by heating a sample up to $140 \text{ }^{\circ}\text{C}$ is not stable.

Thus, the present invention further relates to the crystalline trihydrochloride salt of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide,

35

characterised by a melting point of $T_{m.p.} = 245 \pm 5^{\circ}\text{C}$ (determined by DSC; evaluation using peak-maximum; heating rate: $10^{\circ}\text{C}/\text{min}$).

Solid state stability

5

When testing the stability of the crystalline trihydrochloride hydrated salt form of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide under harsh stress conditions (24 hours at 105°C , 72 hours at 70°C and $> 90\%$ rel.

10 humid., or 24 hours in a Xenotester ($\lambda = 300 - 800 \text{ nm}$, $250 \text{ W}\cdot\text{m}^{-2}$)), the results show that the trihydrochloride hydrated salt of N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide is very stable in the solid state. No significant decomposition or impurities ($\Sigma < 2.4\%$) can be observed under the applied
15 stress conditions.

From the above data, it can be concluded that the hydrated form of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-
20 methoxy-benzamide of formula (I) is characterized by its high solubility in acidic and neutral media and its high crystallinity. The crystalline polymorph form is characterized as a trihydrate. The crystalline form is very stable under harsh stress conditions and is readily soluble in physiologically acceptable solvents. Physiologically acceptable solvents are known to the person skilled in the art and comprise, without limitation, for
25 example isotonic salt or sugar containing solutions such as a 0.9% NaCl solution, a 5% glucose or mannitol solution, or a Ringer/lactate solution.

The present invention also relates to the metabolites of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-tetrahydro-5-
30 methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I), to prodrugs of this compound or of these metabolites obtained via, for example, chemical or non-chemical derivatization of the entire molecule or of one or more chemical groups on the molecule, to conjugates of this compound or of these metabolites with a natural or artificial polymer (for example an oligopeptide, a protein or
35 a chemical polymer), and to the use thereof in a pharmaceutical composition.

"Metabolites" are intended to include compounds which are generated from the active parent drug according to formula (I) or other formulas or compounds of the present invention *in vivo* when such parent drug is administered to a mammalian subject.

5 Metabolites provide the same pharmacological effect and include compounds of the present invention wherein for example an alkyl-amino group is replaced by an unsubstituted amino group or the corresponding N-oxide, an ester group is replaced by the corresponding carboxylate, or a methyl group has been transformed into a hydroxymethyl or a carboxyl group.

10

"Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) or other formulas or compounds of the present invention *in vivo* when such prodrug is administered to a mammalian subject.

Prodrugs of a compound of the present invention, for example the compound of
15 formula (I), are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound.

"Conjugates" are intended to include any covalently bonded natural or artificial polymer
20 (for example an oligopeptide, a protein or a chemical polymer) which release the active parent drug according to formula (I) or other formulas or compounds of the present invention *in vivo* when such conjugate is administered to a mammalian subject.

Conjugates of a compound of the present invention, for example formula (I), are prepared by attaching functional groups present in the compound to an oligopeptide, a
25 protein or a polymer in such a way that the modifications are cleaved *in vivo* by a biomolecule, which usually is found in the vicinity of the target, to the parent compound.

Like the dihydropteridinone derivatives mentioned in WO 2004/076454, the compound
N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[7R)-7-ethyl-5,6,7,8-
30 tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide also has, in particular, an inhibiting effect on specific cell cycle kinases. Thus, this compound may be used for example to treat diseases connected with the activity of specific cell cycle kinases and characterised by excessive or abnormal cell proliferation, and especially for treating diseases connected with the activity of the polo-
35 like kinase PLK-1. Such diseases include, for example: viral infections (e.g. HIV and

Kaposi's sarcoma); inflammatory and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphoma and solid tumours; skin diseases (e.g. psoriasis); bone diseases; cardiovascular diseases (e.g. restenosis and hypertrophy).

- 5 This compound is also suitable for protecting proliferating cells (e.g. hair, intestinal, blood and progenitor cells) from damage to their DNA caused by radiation, UV treatment and/or cytostatic treatment (Davis et al., 2001). It may be used for the prevention, short-term or long-term treatment of the abovementioned diseases, also in combination with other active substances used for the same indications, e.g.
- 10 cytostatics.

Furthermore, the compounds in accordance with the present invention may be used on their own or in conjunction with other pharmacologically active substances.

- 15 Suitable preparations for the pharmaceutical compositions in accordance with the present invention include for example tablets, capsules, suppositories, solutions, - particularly solutions for injection (s.c., i.v., i.m.) and infusion - elixirs, emulsions or dispersible powders. The proportion of the pharmaceutically active compound(s) should be in the range from 0.01 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the
- 20 composition as a whole, i.e. in amounts which are sufficient to achieve the dosage necessary to achieve a therapeutic effect. If necessary the doses specified may be given several times a day.

- Suitable tablets may be obtained, for example, by mixing the active substance(s) with
- 25 known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.

- 30 Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the
- 35 tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.

Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange
5 extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.

Solutions for injection and infusion are prepared in the usual way, e.g. with the addition
10 of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection
15 vials or ampoules or infusion bottles.

Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.

20 Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.

Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils
25 (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium
30 stearate, talc, stearic acid and sodium lauryl sulphate).

The preparations are administered by the usual methods, preferably by oral route, by injection or transdermally. For oral administration the tablets may of course contain,
35 apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for

the tableting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.

- 5 For parenteral use, solutions of the active substances with suitable liquid carriers may be used.

The dosage for intravenous use is from 1 - 1000 mg per hour, preferably between 5 and 500 mg per hour.

10

However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum
15 dose given above, whereas in other cases the upper limit may have to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.

The following examples of formulations illustrate the present invention without
20 restricting its scope.

A)	<u>Tablets</u>	<u>per tablet</u>
	active substance	100 mg
25	lactose	140 mg
	maize starch	240 mg
	polyvinylpyrrolidone	15 mg
	magnesium stearate	5 mg
30		500 mg

The finely ground active substance, lactose and some of the maize starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the
35 remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

	B)	<u>Tablets</u>	<u>per tablet</u>
		active substance	80 mg
5		lactose	55 mg
		maize starch	190 mg
		microcrystalline cellulose	35 mg
		polyvinylpyrrolidone	15 mg
		sodium-carboxymethyl starch	23 mg
10		magnesium stearate	2 mg
			400 mg


The finely ground active substance, some of the maize starch, lactose, microcrystalline
15 cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and
worked with the remaining maize starch and water to form a granulate which is dried
and screened. The sodium carboxymethyl starch and the magnesium stearate are
added and mixed in and the mixture is compressed to form tablets of a suitable size.

20	C)	<u>Ampoule solution</u>	
		active substance	50 mg
		sodium chloride	900 mg
		sodium hydroxide	up to pH 4.0
25		water for inj.	q.s.p. 100 ml

The active substance is dissolved in water at its own pH and sodium chloride is added
to make the solution isotonic. The pH is then adjusted to 4.0 by addition of sodium
hydroxide 1N. The resulting solution is filtered to remove pyrogens and the filtrate is
30 transferred under aseptic conditions into ampoules which are then sterilised and heat-
sealed. The ampoules may contain 5 mg, 25 mg or 50 mg of active substance.


CLAIMS

1. Process for the manufacture of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I)




10


characterised in that a compound of formula **15c**



15 is reacted with a compound of formula **16**,



wherein the compound of formula **16** is prepared by methylation of a compound of formula **8**

8

in the presence of dimethylcarbonate.

5

2. Trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1.

10

3. Crystalline trihydrochloride hydrated forms of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1.

15


4. Crystalline trihydrochloride trihydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1.

20


5. Process for the manufacture of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1, said process comprising the steps of contacting N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide dissolved in a suitable solvent or solvent mixtures, with hydrochloric acid or hydrogen chloride gas dissolved in an organic solvent, and collecting the precipitate formed.

25

6. Process for the manufacture of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1, said process comprising the step of addition
 5 of hydrochloric acid to the reaction medium used for the reaction of the compound **15c**



with the compound **16**



- 10 7. Process in accordance with claim 5 or 6, comprising an additional step of purification via crystallization of the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1, comprising the steps of:

15

suspending the compound of formula (I) as trihydrochloride in a suitable organic solvent;

heating the reaction medium to reflux;

20

adding water to the reaction medium;

collecting the precipitate, washing it and drying it.

8. Process for the manufacture of an hydrated crystal form of the trihydrochloride of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1, said process comprising
5 the steps of:

dissolving the compound (I) as base in a suitable organic solvent at room temperature or elevated temperature

10 adding hydrochloric acid to the reaction medium;

cooling the reaction medium;

collecting the precipitate, washing the precipitate, and drying the precipitate.

15

9. Process in accordance with claim 8, wherein the hydrated crystal form is the trihydrate.

10. Pharmaceutical composition containing the trihydrochloride salt, a crystalline trihydrochloride hydrated form or the crystalline trihydrochloride trihydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1, together with one or more pharmaceutically acceptable carriers, diluents or excipients.

25

11. Process for preparing a pharmaceutical composition according to claim 6, characterised in that the trihydrochloride salt, a crystalline trihydrochloride hydrated form or the crystalline trihydrochloride trihydrate form of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.

12. Use of the trihydrochloride salt, a crystalline trihydrochloride hydrated form or
35 the crystalline trihydrochloride trihydrate form of the compound N-[trans-4-[4-

(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridiny]amino]-3-methoxy-benzamide of formula (I) in accordance with claim 1 for preparing a pharmaceutical composition which is suitable for treating excessive or abnormal cell proliferation.